Recent studies indicated the potential of miRNAs including miR223 as potential therapeutic targets for various diseases, such as K+-channel-related cardiovascular disorders (voltage-gated K+ channel, KV4.2/KCND2) and epilepsy (voltage-gated K+ channels, KV2.1/KCNMB1 and KV7.2/KCNQ2) [34,35]. This evidence concerns the gene KCNQ2 and epilepsy.